To accelerate AI adoption, Block intentionally dismantled its siloed General Manager (GM) structure, which had given autonomy to units like Cash App. They centralized into a functional organization to drive engineering excellence, unify policies, and create a strong foundation for a company-wide AI transformation.

To ensure governance and avoid redundancy, Experian centralizes AI development. This approach treats AI as a core platform capability, allowing for the reuse of models and consistent application of standards across its global operations.

Companies run numerous disconnected AI pilots in R&D, commercial, and other silos, each with its own metrics. This fragmented approach prevents enterprise-wide impact and disconnects AI investment from C-suite goals like share price or revenue growth. The core problem is strategic, not technical.

An effective AI strategy pairs a central task force for enablement—handling approvals, compliance, and awareness—with empowerment of frontline staff. The best, most elegant applications of AI will be identified by those doing the day-to-day work.

Effective AI adoption requires a three-part structure. 'Leadership' sets the vision and incentives. The 'Crowd' (all employees) experiments with AI tools in their own workflows. The 'Lab' (a dedicated internal team, not just IT) refines and scales the best ideas that emerge from the crowd.

Many pharma companies have breakthrough AI results in isolated functions, or "pockets of excellence." However, the ultimate competitive advantage will go to the company that first connects these disparate successes into a single, integrated, enterprise-wide AI capability, thereby creating compounded value across the organization.

Many pharma companies allow various departments to run numerous, disconnected AI pilots without a central strategy. This lack of strategic alignment means most pilots fail to move beyond the proof-of-concept stage, with 85% yielding no measurable return on investment.

The relationship between AI startups and pharma is evolving rapidly. Previously, pharma engaged AI firms on a project-by-project, consulting-style basis. Now, as AI models for drug discovery become more robust, pharma giants are seeking to license them as enterprise-wide software suites for internal deployment, signaling a major inflection point in AI integration.

Pharma companies engaging in 'pilotitis'—running random, unscalable AI projects—are destined to fall behind. Sustainable competitive advantage comes from integrating AI across the entire value chain and connecting it to core business outcomes, not from isolated experiments.